{"id":"W4407112593","doi":"10.3389/fimmu.2025.1512189","title":"Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"EMD Serono; Rheinische Friedrich-Wilhelms-Universität Bonn; Westfälische Wilhelms-Universität Münster; MedDay Pharmaceuticals; McGill University; Deutsche Forschungsgemeinschaft; European Commission; University of Alberta; Fresenius Medical Care North America; Alexion Pharmaceuticals; Prothena; Medical Research Council; Teva Pharmaceutical Industries; Regione Toscana; McGill University Health Centre; Bristol-Myers Squibb; National Institute for Health and Care Research; CSL Behring; Biogen; Celgene; Technische Universität Dresden; Bundesministerium für Bildung und Forschung; Merck KGaA; University College London Hospitals NHS Foundation Trust; Sanofi","keywords":"Cladribine; Multiple sclerosis; Medicine; Biomarker; Oncology; Internal medicine; Immunology; Chemistry","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004965746,0.0003089834,0.000579699,0.0003872121,0.0003491757,0.0003797846,0.0001817486,0.0004504849,0.0004458028],"category_scores_gemma":[0.0007845979,0.0002016345,0.000403948,0.0004236541,0.0001348862,0.0002614626,0.0003651032,0.0003898883,0.0001520829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000287957,"about_ca_system_score_gemma":0.0001675989,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002801875,"about_ca_topic_score_gemma":0.003134082,"domain_scores_codex":[0.9997627,0.00006016011,0.00002207417,0.00006516992,0.00005599117,0.00003390768],"domain_scores_gemma":[0.9994903,0.00005543352,0.0001897033,0.00004616122,0.00008982333,0.0001286023],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004574725,0.0004480202,0.9821543,0.00003938116,0.0002328798,0.0002216373,0.0004847924,0.0001014035,0.002275332,0.00001237525,0.0002635569,0.0091916],"study_design_scores_gemma":[0.00005082887,0.0007685598,0.9984475,0.000003192963,0.00006141268,0.0001382198,0.0001258091,0.00009279336,0.0001302365,0.000005933049,0.000170894,0.00000457445],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9994715,0.0001065071,0.00003177702,0.0000152735,0.000001644689,0.00001250619,0.0002301248,0.000003149816,0.0001275148],"genre_scores_gemma":[0.9992106,0.00005993887,0.00008230851,0.00003180914,0.0000076503,0.00001840343,0.0004446412,0.00000126753,0.0001434008],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002801875,"threshold_uncertainty_score":0.005571187,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01811263940915359,"score_gpt":0.2478728675614929,"score_spread":0.2297602281523393,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}